You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股异动丨创新药概念股持续强势,常山药业创历史新高
延续近期强势,A股市场创新药概念股再度走强,创新药板块指数目前已创出历史新高。个股中,星昊医药涨超25%创2018年1月以来新高,睿智医药20CM涨停,常山药业触及涨停且创历史新高,舒泰神涨超12%,海创药业创2023年7月以来新高,罗欣药业、昂利康、众生药业10CM涨停,汇宇制药、百利天恒、盟科药业、万邦医药、苑东生物、益方生物、信立泰等跟涨。中国银河证券研报表示,医药板块经历较长时间调整,整体估值处于较低水平,且公募持仓低配,2025年在支持引导商保发展的政策背景下,支付端有望边际改善,创新药械有望获益。医药行情将迎来持续性修复,结构性机会依然存在,从短期和中长期确定性增长角度来选择标的,看好创新药产业链在今年持续良好表现。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.